PeptideStack
5.2kquestions
20kanswers
220users

Does headache at week six of dulaglutide usually resolve without a dose change?

Asked 19 Apr 2024Modified 2.3 years agoViewed 46k times
34

Concretely: headache · six · dulaglutide.

I am trying to do this correctly the first time rather than learn it by getting it wrong.

I have already made one mistake here that cost me a vial, so I am being deliberately careful.

What is the correct sequence, and where is the step that people usually skip?

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questionsharm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questionsdulaglutide
dulaglutide

A once-weekly GLP-1 receptor agonist built on an Fc fusion rather than fatty-acid acylation. Use this tag for questions about the fusion-protein…

200 questions
shareeditfollowflag
CM
askedcarys_meredith12k1619 Apr 2024
5Same position here, and I held the step rather than escalating. Watching for better advice. – esther_vandeVelde 6 months ago
4Worth adding whether anything else glucose-lowering is on board. – Dr_Ilse_Vandenberg 4 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 46k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.